Nouvelle déclaration d'incident
No de la demande: 2020-2322
Numéro de référence du titulaire d'homologation: 2019-US-019782
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez l'humain
Pays: UNITED STATES
État: FLORIDA
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 2596-153
Nom du produit: Hartz UltraGuard Rid Flea and Tick Shampoo for Dogs
Liquide
Oui
Inconnu
Site: Personal use / Usage personnel
Non
Autre
Sexe: Femme
Âge: >64 yrs / > 64 ans
Système
Unknown / Inconnu
Oui
Oui
Inconnu
Non professionnel
Application
Aucun
Peau
>6 mos <=1 yr / > 6 mois < = 1 an
>6 mos / > 6 mois
Since approximately 25-Jul-2018, a x year old, female, human, of unknown weight, in unknown condition, with no known concomitant medical conditions, was administered an unknown amount of Hartz UltraGuard Rid Flea and Tick Shampoo for Dogs (Phenothrin), every other day, via the topical route (head to toe) by the patient. The woman was also using unspecified foggers in her home weekly. On approximately 18-Jul-2019, the woman exhibited weakness and was hospitalized. A complete blood count, liver panel and other unspecified blood work had been performed. All lab work values (unspecified) were low and the woman was anemic. She was administered an unknown amount of unspecified intravenous fluids, 2 Units of packed red blood cells, an unknown amount of diethylstilbestrol, folic acid, and Vitamin B12. A bone marrow biopsy had been performed and the results are unknown. The woman's doctors were unaware of product use at the time of the call. On 30-Jul-2019, the woman's daughter called to report that the woman was doing better but that she continued to be hospitalized and additional unspecified tests were still to be run. Informing the woman's doctors of her excessive product use was recommended. No further information was received in this case.
Majeure
Assessment: The active ingredient in this product is present in very low concentration and is poorly absorbed across the skin. Though the product is not intended to be used on humans, especially chronically as described in this case, it is not expected to cause generalized weakness and anemia requiring hospitalization and a transfusion. Common signs following exposure in humans can include dermal irritation, tingling sensation on the skin, eye irritation, or GI upset. Other causes should continue to be considered in this case. The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and can not form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.